HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P R Flatt Selected Research

gastric inhibitory polypeptide receptor

2/2015Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice.
8/2013Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes.
8/2011Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide.
9/2010Active immunization against (Pro(3))GIP improves metabolic status in high-fat-fed mice.
9/2009Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.
6/2009Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.
11/2008(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.
7/2008Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?
4/2008Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.
11/2007Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P R Flatt Research Topics

Disease

34Insulin Resistance
01/2020 - 12/2002
34Type 2 Diabetes Mellitus (MODY)
10/2016 - 06/2000
33Body Weight (Weight, Body)
01/2020 - 09/2000
29Obesity
12/2019 - 02/2003
7Glucose Intolerance
01/2015 - 09/2000
3Necrosis
05/2006 - 04/2002
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
09/2015 - 02/2000
2Hyperphagia (Overeating)
02/2011 - 04/2008
2Diabetes Mellitus
12/2002 - 01/2001
1Neurodegenerative Diseases (Neurodegenerative Disease)
12/2019
1Inflammation (Inflammations)
12/2019
1Cognitive Dysfunction
04/2015
1Morbid Obesity
05/2013
1Hyperinsulinism (Hyperinsulinemia)
11/2008
1Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2006
1Vascular Diseases (Vascular Disease)
05/2006
1Insulinoma
12/2002
1Hyperglycemia
01/2001

Drug/Important Bio-Agent (IBA)

36Glucose (Dextrose)FDA LinkGeneric
01/2020 - 09/2000
32Insulin (Novolin)FDA Link
12/2019 - 02/2000
16Peptides (Polypeptides)IBA
01/2019 - 01/2001
14Glucagon-Like Peptide 1 (GLP 1)IBA
12/2019 - 12/2003
12gastric inhibitory polypeptide receptorIBA
02/2015 - 07/2007
11Hormones (Hormone)IBA
12/2019 - 12/2003
10Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA
02/2015 - 07/2007
10Pro(3)- glucose-dependent insulinotropic polypeptideIBA
02/2015 - 02/2003
9Biological ProductsIBA
01/2019 - 09/2000
7IncretinsIBA
01/2019 - 02/2003
5Glucagon (Glukagon)FDA Link
10/2016 - 01/2001
5Triglycerides (Triacylglycerol)IBA
04/2015 - 09/2009
5(pGlu-Gln)-CCK-8IBA
08/2013 - 10/2012
5glycated insulinIBA
02/2006 - 09/2000
3Exenatide (Byetta)FDA Link
12/2019 - 08/2010
3LipidsIBA
09/2015 - 07/2007
3Insulin SecretagoguesIBA
01/2015 - 01/2001
3monomethoxypolyethylene glycol (MPEG)IBA
08/2013 - 11/2008
3Cholecystokinin (Pancreozymin)IBA
08/2013 - 10/2012
3Hypoglycemic Agents (Hypoglycemics)IBA
09/2002 - 01/2001
2xenin 25 (xenin)IBA
01/2020 - 06/2015
2Carbon MonoxideIBA
10/2016 - 05/2007
2Blood Glucose (Blood Sugar)IBA
01/2016 - 06/2013
2LiraglutideFDA Link
05/2013 - 10/2010
2EnzymesIBA
06/2009 - 12/2003
2exendin (9-39)IBA
05/2005 - 02/2003
2Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
05/2005 - 12/2003
1GastrinsIBA
12/2019
1Neuroprotective AgentsIBA
12/2019
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
12/2019
1apelin-13 peptideIBA
01/2018
1biphalinIBA
01/2016
1Sodium-Glucose Transporter 2 InhibitorsIBA
01/2016
1OxyntomodulinIBA
09/2015
1CholesterolIBA
04/2015
1Sitagliptin Phosphate (Januvia)FDA Link
04/2015
1C-PeptideIBA
10/2014
1Cholecystokinin Receptors (Cholecystokinin Receptor)IBA
08/2013
1Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA
06/2013
1MelanocortinsIBA
06/2013
1Glucagon Receptors (Glucagon Receptor)IBA
06/2013
1Dietary Fats (Dietary Fat)IBA
10/2010
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
12/2009
1Mifepristone (RU 486)FDA Link
12/2009
1Streptozocin (Streptozotocin)FDA Link
04/2008
1Peptide Hormones (Polypeptide Hormones)IBA
05/2007
1GhrelinIBA
05/2007
1Sucrose (Saccharose)IBA
03/2007
1fenugreek seed mealIBA
03/2007
1CarbohydratesIBA
03/2007
1SolutionsIBA
11/2006
1gastric inhibitory polypeptide (3-42)IBA
10/2006
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
06/2006
1HomocysteineIBA
05/2006
1Sorbitol (Yal)FDA Link
09/2005
1Metformin (Glucophage)FDA LinkGeneric
05/2005
1Glucagon-Like Peptide-1 ReceptorIBA
05/2005
1Pharmaceutical PreparationsIBA
08/2004
1N-pyroglutamyl- glucagon-like peptide-1 (7-36)amideIBA
03/2004
1Nateglinide (Starlix)FDA LinkGeneric
09/2003
1SecretagoguesIBA
09/2003
1Cytotoxins (Cytolysins)IBA
12/2002
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
12/2002
1Proteins (Proteins, Gene)FDA Link
12/2002
1Acridine OrangeIBA
12/2002
1Interleukin-1beta (Interleukin 1 beta)IBA
04/2002
1Interferon-gamma (Interferon, gamma)IBA
04/2002
1Adenosine Triphosphate (ATP)IBA
04/2002
1CytokinesIBA
04/2002
1glucagon-like peptide 1 (7-37)IBA
01/2001
1Succinic Acid (Succinate)IBA
01/2001
1EstersIBA
01/2001
1Bovine Serum AlbuminIBA
02/2000
1Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA
02/2000
1AntibodiesIBA
02/2000
1Alanine (L-Alanine)FDA Link
02/2000
1AutoantibodiesIBA
02/2000
1Culture MediaIBA
02/2000

Therapy/Procedure

8Therapeutics
01/2018 - 01/2001
3Injections
10/2016 - 10/2012
2Drug Therapy (Chemotherapy)
12/2019 - 09/2005
1Intraperitoneal Injections
09/2000